Blinatumomab
- Generic Name
- Blinatumomab
- Brand Names
- Blincyto
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 853426-35-4
- Unique Ingredient Identifier
- 4FR53SIF3A
- Background
Blinatumomab is a BiTE-class (bi-specific T-cell engager) constructed monoclonal antibody formed by the recombinant fusion of an anti-CD3 single-chain variable fragment (scFV) and an anti-CD19 scFV through a short peptide linker. CD3 is an antigen expressed on the surface of T-cells, while CD19 is mostly expressed on the surface of malignant B-cells. Since b...
- Indication
Blinatumomab is indicated for the treatment of adults and children with relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL). It is also indicated in adults and children for the treatment of CD19-positive B-cell precursor ALL in first or second complete remission with minimal residual disease (MRD) greater than or equal to...
- Associated Conditions
- Precursor B-lymphoblastic leukaemia acute, Refractory B-cell precursor acute lymphoblastic leukemia, Relapsed B cell precursor Acute lymphoblastic leukemia
- Associated Therapies
- -
Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Elderly/Unfit Ph- B-ALL
- First Posted Date
- 2024-04-26
- Last Posted Date
- 2024-04-26
- Target Recruit Count
- 53
- Registration Number
- NCT06387121
Blinatumomab for Relapsed Acute B Lymphoblastic Leukemia After Transplantation
- First Posted Date
- 2024-04-01
- Last Posted Date
- 2024-04-01
- Lead Sponsor
- Suping ZHANG
- Target Recruit Count
- 60
- Registration Number
- NCT06339775
- Locations
- 🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhenzhou, Henan, China
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Conditions
- Interventions
- Procedure: Biospecimen CollectionDrug: Asparaginase Erwinia chrysanthemiProcedure: Bone Marrow AspirationProcedure: Computed TomographyBiological: BlinatumomabDrug: Calaspargase PegolDrug: CyclophosphamideDrug: CytarabineDrug: DaunorubicinDrug: PrednisoloneDrug: DexamethasoneDrug: PrednisoneDrug: DoxorubicinProcedure: EchocardiographyProcedure: FDG-Positron Emission TomographyDrug: LeucovorinProcedure: Lumbar PunctureProcedure: Magnetic Resonance ImagingDrug: MercaptopurineDrug: MethotrexateProcedure: Multigated Acquisition ScanDrug: PegaspargaseDrug: Therapeutic HydrocortisoneDrug: ThioguanineDrug: VenetoclaxDrug: Vincristine
- First Posted Date
- 2024-03-19
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 171
- Registration Number
- NCT06317662
Phase II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2024-03-13
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT06308588
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab
- Conditions
- Interventions
- First Posted Date
- 2024-03-01
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT06287229
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
A Study Comparing the Combination of Dasatinib and Chemotherapy Treatment With or Without Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or Philadelphia Chromosome-Like (Ph-Like) ABL-Class B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Conditions
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow BiopsyBiological: BlinatumomabDrug: Calaspargase PegolDrug: CyclophosphamideDrug: CytarabineDrug: DasatinibDrug: DaunorubicinDrug: DoxorubicinProcedure: EchocardiographyDrug: LeucovorinDrug: MercaptopurineDrug: MethotrexateProcedure: Multigated Acquisition ScanDrug: PegaspargaseDrug: PrednisoloneDrug: PrednisoneDrug: VincristineRadiation: Radiation TherapyDrug: Thioguanine
- First Posted Date
- 2023-11-09
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 680
- Registration Number
- NCT06124157
Prospective, Single-arm, Multicenter Clinical Study on Haploidentical Hematopoietic Stem Cell Transplantation in Patients With MRD Positive CD19+ALL Treated With Conditioning Regimens Containing Blinatumomab
- First Posted Date
- 2023-11-09
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- Zhejiang University
- Target Recruit Count
- 31
- Registration Number
- NCT06125106
- Locations
- 🇨🇳
The first affiliated hospital of medical college of zhejiang university, Hangzhou, Zhejiang, China
Short-term Blinatumomab as a Bridge Therapy for Allo-HSCT in Low Burden B-ALL
- First Posted Date
- 2023-11-01
- Last Posted Date
- 2023-11-01
- Lead Sponsor
- Sichuan University
- Target Recruit Count
- 20
- Registration Number
- NCT06111625
- Locations
- 🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China
Immune Reconstitution After Allo-HSCT and Blinatumomab
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Sichuan University
- Target Recruit Count
- 20
- Registration Number
- NCT06075212
Blinatumomab Prevents Recurrence of R/R ALL After Allo-HSCT
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Sichuan University
- Target Recruit Count
- 68
- Registration Number
- NCT06075238
- Locations
- 🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.